London
· Delayed Price · Currency is GBP · Price in USD Heron Therapeutics Statistics
Total Valuation
Heron Therapeutics has a market cap or net worth of GBP 201.29 million. The enterprise value is 288.46 million.
| Market Cap | 201.29M |
| Enterprise Value | 288.46M |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +16.83% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 115.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.82 |
| EV / Sales | 2.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -40.22 |
Financial Position
The company has a current ratio of 2.28
| Current Ratio | 2.28 |
| Quick Ratio | 1.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -18.54 |
| Interest Coverage | -1.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2.31% |
| Return on Capital (ROIC) | -3.58% |
| Revenue Per Employee | 815,600 |
| Profits Per Employee | -165,605 |
| Employee Count | 126 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.39% in the last 52 weeks. The beta is 1.81, so Heron Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.81 |
| 52-Week Price Change | -20.39% |
| 50-Day Moving Average | 1.49 |
| 200-Day Moving Average | 2.31 |
| Relative Strength Index (RSI) | 53.71 |
| Average Volume (20 Days) | 19,773 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.61 |
Income Statement
In the last 12 months, Heron Therapeutics had revenue of GBP 102.77 million and -20.87 million in losses. Loss per share was -0.14.
| Revenue | 102.77M |
| Gross Profit | 48.77M |
| Operating Income | -6.21M |
| Pretax Income | -20.87M |
| Net Income | -20.87M |
| EBITDA | -4.25M |
| EBIT | -6.21M |
| Loss Per Share | -0.14 |
Balance Sheet
The company has 52.89 million in cash and 132.99 million in debt, giving a net cash position of -80.10 million.
| Cash & Cash Equivalents | 52.89M |
| Total Debt | 132.99M |
| Net Cash | -80.10M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -29.85M |
| Book Value Per Share | -0.20 |
| Working Capital | 81.80M |
Cash Flow
In the last 12 months, operating cash flow was -6.19 million and capital expenditures -983,360, giving a free cash flow of -7.17 million.
| Operating Cash Flow | -6.19M |
| Capital Expenditures | -983,360 |
| Free Cash Flow | -7.17M |
| FCF Per Share | n/a |
Margins
Gross margin is 47.45%, with operating and profit margins of -6.04% and -20.30%.
| Gross Margin | 47.45% |
| Operating Margin | -6.04% |
| Pretax Margin | -20.30% |
| Profit Margin | -20.30% |
| EBITDA Margin | -4.13% |
| EBIT Margin | -6.04% |
| FCF Margin | n/a |
Dividends & Yields
Heron Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.83% |
| Shareholder Yield | -16.83% |
| Earnings Yield | -10.37% |
| FCF Yield | -3.56% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Heron Therapeutics has an Altman Z-Score of -10.32. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.32 |
| Piotroski F-Score | n/a |